A morphological screening of protein crystals for interferon delivery by metal ion-chelate technology

Drug Development and Industrial Pharmacy

Volumn 36, Issue 12, 2010, Pages 1389-1397

  Jiang, Yanbo ^a   Shi, Kai ^a   Wang, Shuo ^a   Li, Xuefeng ^a   Cui, Fude ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioactivity; Crystallization; Interferon; Morphology; Sustained release

Indexed keywords

BUFFER; METAL ION; RECOMBINANT ALPHA2B INTERFERON; ZINC ION;

ANTIVIRAL ACTIVITY; ARTICLE; CHELATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IONIC STRENGTH; PH MEASUREMENT; SUSTAINED DRUG RELEASE;

ANTIVIRAL AGENTS; CATIONS, DIVALENT; CELLS, CULTURED; CHELATING AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DIFFUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON ALFA-2B; VESICULOVIRUS; ZINC;

EID: 78149362693     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.481303     Document Type: Article

References (34)

1. Degim IT, Celebi N. (2007). Controlled delivery of peptides and proteins. Curr Pharm Des, 13:99-117.
2. Rathore N, Rajan RS. (2008). Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog, 24:504-14.
3. Greenwald RB, Choe YH, McGuire J, Conover CD. (2003). Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev, 55:217-50.
4. Chemmanur AT, Wu GY. (2006). Drug evaluation: Albuferonalpha-an antiviral interferon-alpha/albumin fusion protein. Curr Opin Investig Drugs, 7:750-8.
5. Sheshala R, Peh KK, Darwis Y. (2009). Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery. Drug Dev Ind Pharm, 35:1364-74.
6. Sinha VR, Trehan A. (2003). Biodegradable microspheres for protein delivery. J Control Release, 90:261-80.
7. Basu SK, Govardhan CP, Jung CW, Margolin AL. (2004). Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther, 4:301-17.
8. Jen A, Merkle HP. (2001). Diamonds in the rough: Protein crystals from a formulation perspective. Pharm Res, 18:1483-8.
9. Brader ML, Sukumar M, Pekar AH. (2002). Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol, 20:800-4.
10. Ferrantini M, Capone I, Belardelli F. (2007). Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie, 89:884-93.
11. Samuel CE. (2001). Antiviral actions of interferons. Clin Microbiol Rev, 14:778-809.
12. Sánchez A, Tobío M, González L, Fabra A, Alonso MJ. (2003). Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci, 18:221-9.
13. Thote AJ, Chappell JT Jr, Gupta RB, Kumar R. (2005). Reduction in the initial-burst release by surface crosslinking of PLGA microparticles containing hydrophilic or hydrophobic drugs. Drug Dev Ind Pharm, 31:43-57.
14. Qiu J, Wei XH, Geng F, Liu R, Zhang JW, Xu YH. (2005). Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b. Acta Pharmacol Sin, 26:1395-401.
15. Vyas SP, Rawat M, Rawat A, Mahor S, Gupta PN. (2006). Pegylated protein encapsulated multivesicular liposomes: A novel approach for sustained release of interferon a. Drug Dev Ind Pharm, 32:699-707.
16. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, et al. (2001). Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res, 21:1103-15.
17. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. (2000). Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther, 68:556-67.
18. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, et al. (2003). Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon a-2a (PEGASYS). Protein Expr Purif, 30:78-87.
19. Luft JR, DeTitta GT. (1992). HANGMAN: A macromolecular hanging drop vapor diffusion technique. J Appl Crystallogr, 25:324-5.
20. Rubinstein S, Familletti PC, Pestka S. (1981). Convenient assay for interferons. J Virol, 37:755-8.
21. Santana H, Espino Y, Franco A, Furrazola G, Hardy E. (1999). A sandwich-type enzyme-linked immunosorbent assay for the analysis of recombinant human interferon a-2b. Biotechnol Tech, 5:341-6.
22. Chen X, Matteucci ME, Lo CY, Johnston KP, Williams RO 3rd. (2009). Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev Ind Pharm, 35:283-96.
23. Umeda Y, Fukami T, Furuishi T, Suzuki T, Tanjoh K, Tomono K. (2009). Characterization of multicomponent crystal formed between indomethacin and lidocaine. Drug Dev Ind Pharm, 35(7):843-51.
24. McPherson A. (1990). Current approaches to macromolecular crystallization. Eur J Biochem, 189:1-23.
25. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, et al. (1996). Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure, 4:1453-63.
26. Wiencek JM. (1999). New strategies for protein crystal growth. Annu Rev Biomed Eng, 1:505-34.
27. Asherie N. (2004). Protein crystallization and phase diagrams. Methods, 34:266-72.
28. McPherson A. (1985). Crystallization of macromolecules: General principles. Methods Enzymol, 114:112-20.
29. Kantardjieff KA, Rupp B. (2004). Protein isoelectric point as a predictor for increased crystallization screening efficiency. Bioinformatics, 20:2162-8.
30. Santana H, Martínez E, Sánchez JC, Moya G, Sosa R, Hardy E. (1999). Molecular characterization of recombinant human interferon alpha-2b produced in Cuba. Biotecnol Apl, 16:154-9.
31. Smatanova IK. (2002). Crystallization of biological macromolecules. Mater Struct, 9:14-5.
32. Chayen NE. (1998). Comparative studies of protein crystallization by vapour-diffusion and microbatch techniques. Acta Crystallogr D Biol Crystallogr, 54:8-15.
33. Sauter C. (1999). Additives for the crystallization of proteins and nucleic acids. J Cryst Growth, 196:365-76.
34. Watanabe H, Hori A, Seno M, Kozai Y, Igarashi K, Ichimori Y, et al. (1991). A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun, 175:229-35.